Discover eight allergy companies leading the way in 2026, developing allergy therapies that go beyond emergency management.

From probiotics to do-it-yourself IgG test kits, social media is misinforming patients about how to diagnose and manage ...

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing ...

WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office strengthens patent protection of ATP-R13 Progress ...

Allergy Therapeutics ( (GB:AGY)) just unveiled an update. Allergy Therapeutics has secured shareholder approval at its general meeting to allot up to 610 million new ordinary shares, representing ...

Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in treatment of seasonal allergic rhinitis Study meets both primary and ...

GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT Therapeutics in a deal that values the California biotech at more than two billion ...

NEW YORK, Feb. 12, 2026 /PRNewswire-PRWeb/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that ...

The positions in the table below reflect the Allergy Therapeutics PLC's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to ...